US Patent 5,958,951: Tiagabine Hydrochloride Crystal Form, Claim Scope, Expiration, and Patent Landscape

US Patent 5,958,951 protects a specific anhydrous crystalline form of tiagabine hydrochloride, the active pharmaceutical ingredient in Gabitril. Its core protection is polymorph-specific rather than directed broadly to tiagabine, the underlying nipecotic-acid derivative, or every tiagabine salt. The patent issued on September 21, 1999, from an application claiming an effective September 20, 1996 priority date, and its 20-year term expired in September 2016, subject to any applicable patent-term adjustment or extension. The patent therefore no longer creates an enforceable US exclusionary right.

The claims cover four principal subject areas:

The specified anhydrous crystalline tiagabine hydrochloride form.
A solvent-free or substantially solvent-free version of that form.
A precipitation process using aqueous hydrochloric acid.
Pharmaceutical compositions and therapeutic methods using the claimed crystal form.

The patent remains relevant for historical freedom-to-operate analysis, polymorph identification, infringement disputes involving the historical US market, and evaluation of the original Gabitril development program. It does not currently block generic tiagabine hydrochloride manufacture or sale in the United States.

What compound and crystal form does US Patent 5,958,951 protect?

The patent protects the R-enantiomer of tiagabine hydrochloride in a defined anhydrous crystalline form.

The chemical name recited in the claims is:

R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid hydrochloride

This is tiagabine hydrochloride. Tiagabine is a selective inhibitor of GABA uptake and was developed as an antiseizure medicine. The FDA approved Gabitril for adjunctive treatment of partial seizures in adults and children age 12 years and older, although the approved labeling and safety profile have changed over time. [2]

The patent does not claim all forms of tiagabine hydrochloride. It claims a crystalline form identified through a set of X-ray powder diffraction peaks:

Claimed XRPD peak positions
6.4
11.3
13.0
13.9
15.0
18.7
19.4
22.5
23.7

The claims identify the diffraction pattern as obtained with KBr. The patent’s technical focus is therefore solid-state form control, not merely chemical identity.

Why the XRPD limitation matters

A chemical compound claim generally covers molecules defined by structure. A polymorph claim covers a particular physical arrangement of those molecules in the solid state. Two products can contain the same active molecule but fall within different patent positions if they differ in crystal structure, hydration state, solvent inclusion, or amorphous character.

Claim 1 is a product claim. A product would generally need to satisfy both elements:

It must be anhydrous crystalline R(-)-tiagabine hydrochloride.
It must have substantially the identified XRPD peaks.

A material that contains tiagabine hydrochloride but is amorphous, hydrated, solvated, or a different polymorph would not necessarily fall within claim 1.

What are the individual claims of US Patent 5,958,951?

Claim 1: Anhydrous crystalline tiagabine hydrochloride

Claim 1 covers the specified anhydrous crystalline form identified by the nine XRPD peaks.

The claim is narrower than a claim to tiagabine hydrochloride generally. It does not expressly require a specific particle size, bulk density, tablet formulation, dissolution profile, manufacturing scale, or therapeutic indication.

The phrase "substantially the following X-ray powder diffraction peaks" creates the main claim-construction issue. The claim does not state numerical tolerances for peak position, relative intensity, or peak breadth. In an infringement analysis, the comparison would ordinarily consider the complete diffraction pattern, instrument conditions, sample preparation, calibration, and whether observed deviations are attributable to normal analytical variation.

Claim 2: Anhydrous and substantially free of bound organic solvent

Claim 2 adds that the crystalline material is "substantially free of bound organic solvent."

This limitation distinguishes the claimed material from a solvate or crystal lattice containing an organic solvent. The claim is narrower than claim 1 because it includes an additional solid-state characteristic.

The word "bound" is significant. It suggests solvent incorporated into the crystal structure rather than merely solvent remaining on the surface or trapped in a manufacturing batch. A residual-solvent test alone would not necessarily establish whether the solvent is structurally bound. Relevant evidence could include:

Thermogravimetric analysis.
Karl Fischer water analysis.
Gas chromatography for residual organic solvents.
Differential scanning calorimetry.
Solid-state NMR.
Comparison with known solvated crystal forms.

The claim also uses "substantially free," rather than an absolute zero-solvent requirement. That wording generally requires a quantitative and technical assessment rather than proof that no solvent molecule is present under any circumstances.

Claim 3: Preparation process

Claim 3 covers a process for preparing the claimed anhydrous crystalline form by:

Dissolving tiagabine hydrochloride in an aqueous hydrochloric acid solution; and
Precipitating tiagabine hydrochloride from that solution.

The claim is both process-limited and product-limited. The process must include the specified aqueous hydrochloric acid dissolution and precipitation steps, and the resulting material must have the claimed XRPD characteristics.

The use of "comprises" makes the process open-ended. Additional steps, such as filtration, washing, drying, milling, particle-size classification, or packaging, would not ordinarily avoid the claim if the two required steps are present and the claimed product is produced.

The claim does not specify:

Hydrochloric acid concentration.
Temperature.
Dissolution time.
Seeding.
Cooling rate.
Agitation.
pH endpoint.
Precipitation solvent ratio.
Drying temperature.
Water activity.
Scale.

Those variables may affect whether the process actually produces the claimed crystalline form. They also provide potential design-around or non-infringement positions if a different solid form results.

Claims 4 and 5: Pharmaceutical compositions

Claim 4 covers a pharmaceutical composition containing:

A therapeutically effective amount of the claimed crystalline salt; and
A pharmaceutically acceptable carrier or diluent.

Claim 5 narrows claim 4 to a dosage unit containing approximately 1.0 to 1,500 mg of active ingredient.

These claims are formulation claims, but they are not detailed formulation-platform claims. They do not require a particular excipient, coating, release profile, tablet geometry, capsule shell, granulation process, or dissolution specification.

The dosage range is broad. Gabitril tablets were marketed in substantially lower strengths than the upper limit of 1,500 mg. The claim therefore covers a wide theoretical dosage-unit range, although commercial infringement analysis would focus on products that contain the claimed crystal form and satisfy the dosage limitation.

Claims 6 and 7: Therapeutic methods

Claim 6 covers administering an effective amount of the claimed crystalline salt to inhibit GABA uptake in a mammal.

Claim 7 covers administering the composition of claim 4 for the same purpose.

These claims are not limited expressly to epilepsy, partial seizures, a particular patient population, route of administration, treatment duration, or dosing schedule. Their scope is tied to the claimed crystal form and the stated GABA-uptake function.

A product label that does not mention GABA uptake would not automatically resolve all method-of-use issues. The analysis would depend on the approved indication, prescribing information, promotional conduct, instructions, and the relationship between the claimed use and actual use.

How does US Patent 5,958,951 compare with broad tiagabine patents?

The patent should be separated from earlier patents directed to the underlying tiagabine compound and its therapeutic activity.

Patent category	Typical subject matter	Relationship to US 5,958,951
Composition-of-matter patents	Tiagabine or related nipecotic-acid derivatives	Broader chemical protection, generally earlier-expiring
Stereochemical patents	R-enantiomer or selected stereoisomer	May overlap at the molecule level but not necessarily the crystal form
Salt patents	Hydrochloride or other pharmaceutically acceptable salts	Potentially broader than the specific anhydrous polymorph
Polymorph patents	Defined XRPD, thermal, or solvent characteristics	Closest technical category
Process patents	Crystallization, purification, or isolation methods	May overlap with claim 3
Formulation patents	Tablets, coatings, modified release, or excipient systems	Potentially separate from claims 4 and 5
Method-of-use patents	Epilepsy, seizure, neuropathic pain, or other GABA-related uses	Potentially separate from claims 6 and 7

The strategic value of US 5,958,951 was likely greatest after broader compound protection had expired or approached expiration. A polymorph patent can delay generic entry if the marketed reference product uses the claimed form and an abbreviated new drug application relies on that product.

That value ended when the patent term expired.

When did US Patent 5,958,951 expire?

The patent issued on September 21, 1999. Its relevant priority date is September 20, 1996. Under the post-URAA 20-year patent-term framework, the base term ran to approximately September 20, 2016, subject to any patent-term adjustment, patent-term extension, or terminal disclaimer recorded in the official patent file.

Public patent databases identify the patent as expired. The Orange Book patent listing for Gabitril is therefore historical rather than an active barrier to US generic approval or launch. [1][3]

Event	Date
Effective priority date	September 20, 1996
US filing period	1997
Patent issued	September 21, 1999
Approximate base expiration	September 20, 2016
Current status	Expired

A patent expiration analysis should distinguish expiration from abandonment, disclaimer, invalidity, or unenforceability. Here, the commercial conclusion is the same: US Patent 5,958,951 is no longer enforceable as an exclusionary patent.

What was the Orange Book status of Gabitril?

Gabitril, containing tiagabine hydrochloride, was approved under FDA NDA 020646. The product was marketed as tablets in multiple strengths, including 2 mg, 4 mg, 12 mg, and 16 mg strengths according to FDA labeling. [2]

The Orange Book historically listed US Patent 5,958,951 for Gabitril. An Orange Book listing does not determine patent validity or infringement. It identifies patents submitted by the NDA holder or applicant as potentially claiming the approved drug or an approved method of use under the Hatch-Waxman framework.

The listing created potential Paragraph IV exposure for an ANDA applicant before expiration. After expiration, the listing no longer prevents approval or commercial launch based on the patent.

FDA approval and patent status are separate:

FDA approval establishes safety, effectiveness, pharmaceutical quality, and regulatory compliance.
Orange Book listing identifies submitted patent information.
Patent enforceability depends on patent term, validity, infringement, and statutory defenses.
A generic applicant may challenge a listed patent through a Paragraph IV certification.
Patent expiration removes the ordinary infringement barrier regardless of whether a Paragraph IV dispute occurred.

Were there Paragraph IV challenges to US Patent 5,958,951?

A Paragraph IV certification would assert that the listed patent is invalid, unenforceable, or not infringed. The applicant would need to address the patent claims most relevant to its product or manufacturing process.

For this patent, the principal Paragraph IV issues would have been:

Whether the generic product contained the claimed anhydrous crystal form.
Whether the product showed the specified XRPD peaks.
Whether any solvent was bound in the crystal.
Whether the generic manufacturing process used dissolution in aqueous hydrochloric acid followed by precipitation.
Whether the commercial product satisfied the composition or method claims.

The patent’s formulation and method claims could have created additional certification questions. A generic tablet containing the same reference-product solid form might implicate claim 4 or claim 5 even if its excipients differed.

There is no current commercial Paragraph IV barrier because the patent has expired. Historical ANDA litigation, if any, would need to be assessed from PACER, district-court dockets, and FDA Paragraph IV notice records. The expired status is dispositive for present US launch planning.

What patent litigation affected Gabitril and tiagabine?

The central litigation risk associated with US Patent 5,958,951 would have involved generic tiagabine tablets and the relationship between the reference product’s solid form and an ANDA applicant’s product.

The technical disputes would likely have centered on:

XRPD peak matching.
The meaning of "substantially."
Whether the claimed form was anhydrous.
Whether organic solvent was bound in the lattice.
Whether the accused process included the claimed aqueous hydrochloric acid precipitation sequence.
Whether the patent was anticipated or obvious over earlier tiagabine hydrochloride preparations.
Whether the claims were enabled across the full claimed XRPD and dosage ranges.

Polymorph patents are often vulnerable to prior-art and obviousness arguments where the claimed form was an expected result of routine crystallization screening. They can be stronger when the patent demonstrates unexpected stability, purity, manufacturability, hygroscopicity, or therapeutic advantages.

No active US litigation based on this patent can currently support an injunction against a generic product because the patent term has ended.

How strong were the claims and patent estate?

Claim-strength assessment

Claim	Technical breadth	Main strength	Main vulnerability
1	Moderate	Direct product claim to a defined polymorph	XRPD tolerance and identity disputes
2	Narrower than claim 1	Adds solvent-free characteristic	"Substantially free" construction and testing
3	Moderate	Covers an identified isolation route	Design-around through different crystallization conditions
4	Broad composition claim	Captures pharmaceutical use of the crystal form	Limited by requirement for the claimed form
5	Broad dosage range	Covers many dosage-unit configurations	Potential written-description or practical-scope disputes at extremes
6	Broad method claim	Covers GABA-uptake inhibition using the crystal	Proof of use and product-form limitations
7	Broad method/composition claim	Links therapeutic use to composition	Same product and inducement limitations

The strongest commercial claim was likely claim 1 because it directly targeted the solid form used in the marketed product. Claims 4 and 5 could support product-level infringement theories against tablets containing that form. Claim 3 would matter most if a generic used the patented precipitation sequence.

The patent was not a complete tiagabine estate. It did not by itself control:

All tiagabine salts.
All tiagabine polymorphs.
Amorphous tiagabine hydrochloride.
Every manufacturing route.
Every tiagabine formulation.
Every use of the tiagabine molecule.

What generic launch risks existed?

Before expiration, a generic applicant faced several possible launch scenarios.

Scenario 1: Paragraph III certification

The applicant could acknowledge the patent and defer approval or launch until expiration. This was the lowest litigation-risk pathway but delayed market entry.

Scenario 2: Paragraph IV certification

The applicant could challenge the patent as invalid, unenforceable, or not infringed. The technical basis could include a different polymorph, nonaqueous crystallization, absence of the specified peaks, or prior-art disclosure of the same form.

This route created litigation risk but could support earlier launch if the challenge succeeded or was settled.

Scenario 3: Non-infringing crystal form

A generic manufacturer could develop a different polymorph, hydrate, solvate, amorphous form, or solid dispersion. This approach would require analytical confirmation that the product did not contain the patented XRPD pattern, including after storage and formulation.

Scenario 4: Post-expiration launch

After September 2016, the patent no longer constrained generic entry. A manufacturer could use the same crystal form, subject to other unexpired patents, regulatory requirements, trademarks, manufacturing rights, and ordinary product-liability considerations.

Did this patent create biosimilar risk?

No. Tiagabine hydrochloride is a small-molecule drug, not a biologic. Biosimilar provisions under the Public Health Service Act and Purple Book do not apply.

The relevant competitive pathway was the ANDA process under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Generic applicants could rely on the reference drug’s safety and effectiveness findings while demonstrating pharmaceutical equivalence and bioequivalence. [4]

The patent risk was therefore a conventional small-molecule Hatch-Waxman issue, not a biosimilar interchangeability or biologic-exclusivity issue.

What manufacturing and intellectual-property barriers remain?

US Patent 5,958,951 no longer creates a live patent barrier, but tiagabine manufacturing still requires control of several technical attributes:

Correct R-enantiomer content.
Chemical purity and degradation control.
Residual hydrochloride and solvent control.
Crystal-form consistency.
Water content.
Particle-size distribution.
Tablet dissolution.
Stability under commercial storage.
Reproducible scale-up.

A manufacturer attempting to reproduce the historical reference-product form would need to establish whether the XRPD pattern remains consistent across batches and whether milling, granulation, compression, humidity, or excipient interaction changes the solid state.

Other possible barriers include regulatory exclusivity, manufacturing know-how, supplier qualification, trademarks, and separate patent rights. None of those barriers is established by US Patent 5,958,951 alone.

How does US Patent 5,958,951 compare with current tiagabine exclusivity?

Exclusivity or right	Current relevance
US Patent 5,958,951	Expired
Small-molecule FDA exclusivity	Historical; not a current barrier for the 1997 approval
Orphan-drug exclusivity	Not the principal basis of Gabitril market protection
Pediatric exclusivity	Any historical extension would have ended
Biosimilar exclusivity	Not applicable
Orange Book listing	Historical listing; no active patent term
Trademark rights	Separate from patent protection
Regulatory approval	Remains distinct from patent exclusivity

The relevant present-day conclusion is that tiagabine hydrochloride is exposed to generic competition in the United States, subject to any separate regulatory or intellectual-property rights not established by this patent.

Key Takeaways

US Patent 5,958,951 covers a defined anhydrous crystalline polymorph of tiagabine hydrochloride.
The key identifying limitation is the claimed XRPD peak pattern at 6.4, 11.3, 13.0, 13.9, 15.0, 18.7, 19.4, 22.5, and 23.7.
Claim 2 narrows the product to material substantially free of bound organic solvent.
Claim 3 covers dissolution in aqueous hydrochloric acid followed by precipitation of the claimed form.
Claims 4 and 5 cover pharmaceutical compositions and broad dosage-unit ranges.
Claims 6 and 7 cover GABA-uptake inhibition methods using the claimed crystal form or composition.
The patent expired in approximately September 2016 based on its September 20, 1996 effective priority date.
It is not a biologic patent and creates no biosimilar issue.
Current generic entry is not blocked by this patent.
Historical litigation risk would have centered on XRPD identity, solvent content, polymorph selection, and crystallization process design-around.
The patent was a solid-state form patent, not a broad composition-of-matter patent for all tiagabine products.

FAQs About US Patent 5,958,951 and Tiagabine

Does US Patent 5,958,951 cover all tiagabine hydrochloride?

No. It covers a particular anhydrous crystalline form identified by its XRPD pattern. Other polymorphs, hydrates, solvates, amorphous material, or formulations lacking the claimed form may fall outside claim 1.

Can a manufacturer use the same tiagabine crystal form after patent expiration?

Yes, expiration removes the patent-based exclusionary right. The manufacturer must still satisfy FDA requirements and address any separate active patents, trademarks, regulatory restrictions, and manufacturing obligations.

Is an aqueous hydrochloric acid process required for every product covered by the patent?

No. The aqueous hydrochloric acid dissolution and precipitation steps are specific to process claim 3. Product claim 1 does not require that manufacturing route, although the resulting material must have the claimed crystal characteristics.

Does the patent cover tiagabine tablets containing different excipients?

Potentially, if the tablets contain the claimed crystalline salt and satisfy the limitations of claim 4. The composition claims do not require the original Gabitril excipient system.

Is tiagabine covered by the FDA Purple Book?

No. Tiagabine is a small-molecule drug approved through the NDA pathway. Generic competition is governed by the Orange Book and ANDA framework rather than the Purple Book biosimilar system.

References

United States Patent and Trademark Office. (1999). US Patent No. 5,958,951, crystalline form of tiagabine hydrochloride.
U.S. Food and Drug Administration. (n.d.). Gabitril (tiagabine hydrochloride) prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	0661/96	Jun 14, 1996

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	008236	⤷ Start Trial
Austria	223405	⤷ Start Trial
Australia	3165397	⤷ Start Trial
Australia	723267	⤷ Start Trial
Brazil	9709725	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,958,951

Summary for Patent: 5,958,951